 | Up a level |
Clark, Richard E 
ORCID: 0000-0002-1261-3299, Polydoros, Fotios ORCID: 0000-0001-5181-6817, Apperley, Jane F, Milojkovic, Dragana, Pocock, Christopher, Smith, Graeme, Byrne, Jenny L, de lavallade, Hugues, O'Brien, Stephen G, Coffey, Tony et al (show 2 more authors)
(2017)
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.
The Lancet Haematology, 4 (7).
E310-E316.
Claudiani, Simone, Janssen, Jeroen JWM, Byrne, Jenny, Smith, Graeme, Blijlevens, Nicole, Raghavan, Manoj, Smith, Matthew, Clark, Richard E ORCID: 0000-0002-1261-3299, Mclain-Smith, Susan, Carter, Angela M et al (show 2 more authors)
(2022)
A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands.
EUROPEAN JOURNAL OF HAEMATOLOGY, 109 (1).
pp. 90-99.